A supervised medical decision, not a protocol you download.
GHK-Cu peptide injection is the route people ask about most and understand least. It is not routinely available at HELiXVi, it is not a consumer product, and this page contains no injection sites, no technique, and no self-administration guidance of any kind. What it does explain is how systemic exposure differs from topical use, why supervision is not optional, and what a clinician assesses before the route is even considered. The form we primarily prescribe is topical, explained on our topical GHK-Cu page, and the peptide itself is covered in our GHK-Cu peptide guide. To discuss any of it with a clinician, start at longevity and peptide therapy. GHK-Cu is not FDA-approved.
It is one of the most searched questions on this topic, and the truthful answer is that a web page is the wrong place to get it. Route and site are clinical decisions made by the prescribing clinician for a specific patient, based on the preparation, the indication, and that patient's assessment, and they are directed at the point of care. A stranger on the internet publishing an anatomical map has no idea what is in your vial, what your health history is, or whether you should be injecting anything at all. Copper is an essential mineral with a narrow useful range, and systemic exposure to a copper complex without supervision raises accumulation concerns that topical use largely sidesteps. Add the fact that most injectable GHK-Cu sold online is labeled for research use only and is not manufactured for human administration, and the picture is clear enough. HELiXVi primarily prescribes topical GHK-Cu, and any injectable consideration is prescriber-directed only and is never guaranteed to be offered.
There is no shortage of protocols online written by people with no license and no liability. What is scarce is a clinician who will assess you and tell you honestly when injection is not appropriate. Start at longevity and peptide therapy, and if the topical route is what you were actually looking for, our topical GHK-Cu page is the better place to begin.
Route and site are determined and directed by the prescribing clinician for an individual patient, never chosen by a patient from a web page. We do not publish injection sites or technique.
Topical GHK-Cu is the form we primarily prescribe. Injectable use, if it is considered at all, is strictly prescriber-directed, is not routinely available, and is never guaranteed.
There is no reliable human evidence establishing that. Most published GHK-Cu research is topical or preclinical. Our GHK-Cu before and after page covers what studies actually measured.
Vials sold as research chemicals are not manufactured or labeled for human use, and sterility, identity, and purity are unverified. That is a genuine safety risk, separate from the peptide itself.
We do not publish injectable dose figures. Dosing is set individually by a prescriber after assessment, and the reasoning is explained on our GHK-Cu dosage page.
No. GHK-Cu is not FDA-approved for any route, and compounded preparations are not FDA-approved. Nothing here is intended to diagnose, treat, cure, or prevent any disease.
GHK-Cu is not FDA-approved. This page provides no self-administration, dosing, site, or technique guidance and is not medical advice. Injectable GHK-Cu is not routinely available through HELiXVi and any such use is strictly prescriber-directed. Compounded preparations are prepared by US state-licensed pharmacies and are not FDA-approved. Prescription products require an online consultation with a licensed US clinician where clinically appropriate; approval is not guaranteed. Human research on GHK-Cu is limited and much of it is preclinical or small-scale. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary.
Start your free consultation right now
No clinic visit. Licensed US clinicians. Dispatched within 24 hours of your consultation and payment.